Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Inclusion Criteria:

* Diagnosis of 1 of the following:

  * Histologically confirmed malignant solid tumor at original diagnosis or relapse

    * Measurable or evaluable disease by CT scan or MRI
  * Histologically confirmed leukemia, including 1 of the following:

    * Acute lymphoblastic leukemia (ALL)

      * Greater than 25% blasts in the bone marrow (M3 bone marrow)
    * Acute myeloid leukemia (AML)

      * Greater than 25% blasts in the bone marrow (M3 bone marrow)
    * AML and FLT3-ITD mutation

      * Patients must have ? 5% blasts in the bone marrow
      * Active extramedullary disease (except leptomeningeal disease) allowed
    * Juvenile myelomonocytic leukemia (JMML) meeting the following criteria:

      * Peripheral blood monocytosis \> 1,000/mm\^3
      * Blasts (including promonocytes) are \< 20% of the WBCs in the blood and of the nucleated bone marrow cells
      * No Philadelphia chromosome (Ph) or BCR/ABL fusion gene
      * Has ? 2 of the following additional diagnostic criteria:

        * Hemoglobin F increased for age
        * Immature granulocytes in the peripheral blood
        * WBC \> 10,000/mm\^3
        * Clonal chromosomal abnormality (e.g., may be monosomy 7)
        * Sargramostim (GM-CSF) hypersensitivity of myeloid progenitors in vitro
    * Chronic myelogenous leukemia (CML) in blast crisis

      * Greater than 25% blasts in the bone marrow (M3 bone marrow)
      * Patients with Ph-positive CML must be refractory to imatinib mesylate
* Relapsed or refractory disease

  * Patients with acute promyelocytic leukemia (APL) must be refractory to treatment with tretinoin and arsenic trioxide
* Standard curative therapies or therapies proven to prolong survival with an acceptable quality of life do not exist
* Active extramedullary disease, except active leptomeningeal leukemia, allowed
* No brain tumors or known brain metastases
* Karnofsky performance status (PS) 50-100% (for patients \> 10 years of age)
* Lansky PS 50-100% (for patients ? 10 years of age)
* Patients with solid tumors must have adequate bone marrow function, as defined by the following:

  * Absolute neutrophil count ? 1,000/mm\^3
  * Platelet count ? 75,000/mm\^3 (transfusion independent)
  * Hemoglobin ? 8.0 g/dL (red blood cell \[RBC\] transfusions allowed)
* Patients with leukemia may have abnormal blood counts but must meet the following criteria:

  * Platelet count ? 20,000/mm\^3 (platelet transfusions allowed)
  * Hemoglobin ? 8.0 g/L (RBC transfusions allowed)
* Patients with acute myeloid leukemia and FLT3-ITD mutation

  * Platelet count ? 20,000/mm\^3
* Lipase and amylase normal
* Creatinine clearance or radioisotope glomerular filtration rate ? 70 mL/min OR creatinine normal based on age as follows:

  * No greater than 0.8 mg/dL (for patients 5 years of age and under)
  * No greater than 1.0 mg/dL (for patients 6-10 years of age)
  * No greater than 1.2 mg/dL (for patients 11-15 years of age)
  * No greater than 1.5 mg/dL (for patients over 15 years of age)
* Patients with solid tumors must meet the following criteria:

  * Bilirubin normal for age
  * ALT normal for age (for the purpose of this study, the upper limit of normal \[ULN\] for ALT is 45 ?/L)
  * Serum albumin ? 2 g/dL
* Patients with leukemia must meet the following criteria:

  * Bilirubin (sum of conjugated + unconjugated) ? 1.5 times ULN for age
  * ALT ? 5.0 times ULN for age (? 225 ?/L) (for the purpose of this study, the ULN for ALT is 45 ?/L)
  * Serum albumin ? 2 g/dL
* Albumin ? 2 g/dL
* PT, PTT, and INR normal (for patients on prophylactic anticoagulation)
* No evidence of dyspnea at rest
* No exercise intolerance
* Pulse oximetry \>94% on room air, if there is clinical indication for determination
* Diastolic blood pressure ? the 95th percentile for age and gender (height included for AML and FLT3-ITD mutation patients)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No uncontrolled infection
* Able to swallow tablets
* No evidence of bleeding diathesis
* No other medical condition or situation that would preclude study compliance
* No known Gilbert syndrome
* Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy (for patients with solid tumors)
* Recovered from the non-hematologic toxic effects of all prior therapy (for patients with leukemia)
* Recovered from acute non-hematologic toxic effects of all prior anti-cancer chemotherapy (for patients with AML and FLT3-ITD mutation)
* At least 7 days since prior hematopoietic growth factors
* At least 7 days since prior biologic agents
* At least 2 weeks since prior local palliative radiotherapy (small port)
* At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiation to ? 50% of the pelvis
* At least 6 weeks since other prior substantial bone marrow radiation (e.g., skull, spine, pelvis, ribs)
* At least 3 months since prior stem cell transplantation or rescue (for patients with solid tumors)

  * No evidence of active graft-vs-host disease
* At least 3 months since prior myeloablative therapy followed by bone marrow or stem cell transplantation (for patients with leukemia)
* At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) (for patients with solid tumors)

  * At least 24 hours since prior nitrosoureas (for patients with AML and FLT3-ITD mutation)
* At least 2 weeks since prior chemotherapy (for patients with leukemia)
* At least 3 weeks since prior monoclonal antibody therapy
* No prior sorafenib
* No other concurrent investigational drugs
* No other concurrent anticancer agents or therapies, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

  * Concurrent maintenance-like chemotherapy for patients with AML and FLT3-ITD mutation allowed
* No concurrent administration of any of the following:

  * Cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
  * Rifampin
  * Grapefruit juice
  * Hypericum perforatum (St. John wort)
* No concurrent therapeutic anticoagulation

  * Concurrent prophylactic anticoagulation (e.g., low-dose warfarin) of venous or arterial access devices allowed provided the requirements for PT, INR, or PTT are met